The nurse practitioner is considering adding another medication to the regime of a patient with uncontrolled diabetes. Which of the following is a FALSE statement about canagliflozin (Invokana) an SGLT2 inhibitor?
1) There is a black box warning regarding the risk of amputation
2) This medication is associated with weight loss
3) There is an increased risk of genitourinary infections
4) This medication would be detrimental for a diabetic patient with a comorbid diagnosis of heart failure